Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

Sales of Trelegy Ellipta and Flixotide/Flovent surged 17% and 47%, respectively. Sales of Advair/Seretide and Anoro Ellipta fell 2% each. Revlar/Breo Ellipta sales declined 5%. The decline in ...

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler prescribed for COPD and asthma. Trelegy Ellipta has interactions with some other drugs ...

The 15 drugs for which Medicare will negotiate lower prices that will take effect in 2027 are: Austedo/Austedo XR, Breo Ellipta, Calquence, Ibrance, Janumet/Janumet XR, Linzess, Ofev, Otezla, ...